タバタ ツトム   TABATA Tsutomu
  田畑 務
   所属   医学部 医学科(東京女子医科大学病院)
   職種   教授・基幹分野長
論文種別 原著
言語種別 英語
査読の有無 査読あり
招待の有無 招待あり
表題 Sentinel node navigation surgery in cervical cancer: a systematic review and metaanalysis.
掲載誌名 正式名:International journal of clinical oncology
略  称:Int J Clin Oncol
ISSNコード:14377772/13419625
掲載区分国内
巻・号・頁 27(8),pp.1247-1255
著者・共著者 Chiyoda Tatsuyuki, Yoshihara Kosuke, Kagabu Masahiro, Nagase Satoru, Katabuchi Hidetaka, Mikami Mikio, Tabata Tsutomu, Hirashima Yasuyuki, Kobayashi Yoichi, Kaneuchi Masanori, Tokunaga Hideki, Baba Tsukasa
担当区分 責任著者
発行年月 2022/08
概要 Sentinel node navigation surgery (SNNS) is used in clinical practice for the treatment of cervical cancer. This study aimed to elucidate the appropriate sentinel lymph node (SLN) mapping method and assess the safety and benefits of SNNS. We searched the PubMed, Ichushi, and Cochrane Library databases for randomized controlled trials (RCT) and studies on SLN in cervical cancer from January 2012 to December 2020. Two authors independently assessed study quality and extracted data. We quantitatively analyzed the detection rate, sensitivity/specificity, and complications and reviewed information, including the survival data of SLN biopsy (SLNB) without pelvic lymphadenectomy (PLND). The detection rate of SLN mapping in the unilateral pelvis was median 95.7% and 100% and in the bilateral pelvis was median 80.4% and 90% for technetium-99 m (Tc) with/without blue dye (Tc w/wo BD) and indocyanine green (ICG) alone, respectively. The sensitivity and specificity of each tracer were high; the area under the curve of each tracer was 0.988 (Tc w/wo BD), 0.931 (BD w/wo Tc), 0.966 (ICG), and 0.977 (carbon nanoparticle). Morbidities including lymphedema, neurological symptoms and blood loss were associated with PLND. One RCT and five studies all showed SNNS without systematic PLND does not impair recurrence or survival in early-stage cervical cancer with a tumor size ≤ 2-4 cm. Both Tc w/wo BD and ICG are appropriate SLN tracers. SNNS can reduce the morbidities associated with PLND without affecting disease progression in early-stage cervical cancer.
DOI 10.1007/s10147-022-02178-w
PMID 35612720